Released: 29.04.2019  16:51 GMT
RNS Number: 4588X
Kedrion S.p.A.
29 April 2019

Castelvecchio Pascoli (Lucca, Italy), 29 April 2019 – The Annual General Meeting of Shareholders of Kedrion S.p.A. has approved today the individual financial statements of the Company for the year ended 31 December 2018 and has acknowledged its 2018 consolidated financial statements.

READ THE CONSOLIDATED FINANCIAL STATEMENTS 2018

For further information, please write to investor@kedrion.com   

About Kedrion

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.

Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,600 employees and a commercial presence in approximately 100 countries worldwide.

Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.

Additional information about Kedrion can be found at kedrion.com

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business and assets position of Kedrion S.p.A. and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Kedrion does not intend to update the forward-looking statements and assumes no obligation to do so.